Patent ID: 6015797
Filing Date: 2000-01-18
Classification: A61K

Abstract:
A pharmaceutical composition comprising, as active principle, a combination of an adenosinergic agonist and a compound selected from the group consisting of, a benzodiazepine and an N-Methyl-D-aspartic acid (NMDA) antagonist and a pharmaceutically acceptable carrier or excipient wherein the adenosinergic agonist compound is selected from the group consisting of N-cyclopropyl-1-deoxy-1-[6-[[2-[1-[2-(1-piperidinyl) ethyl] ethyl]-1H-indol-3-yl] ethyl] amino]-9H-purin-9-yl].beta.-D-ribofuranuronamide and N-cyclopropyl-1-deoxy-1-[6-[[2-[1-[(2,5-dimethylphenyl) methyl]-5-methyl-1H-indol-3-yl] ethyl] amino]-9H-purin-9-yl] .beta.-D-ribofuranuronamide.